北 京 大 成 律 师 事 务 所 关 于 华 润 博 雅 生 物 制 药 集 团 股 份 有 限 公 司 2025 年 第 二 次 临 时 股 东 会 的 法 律 意 见 书 法律意见书——博雅生物 2025 年第二次临时股东会 北京大成律师事务所关于华润博雅生物制药集团股份有限 公司 2025 年第二次临时股东会的法律意见书 致：华润博雅生物制药集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范 性文件的要求，北京大成律师事务所（以下简称"本所"）接受华润博雅生物制 药集团股份有限公司（以下简称"公司"）的委托，指派律师参加公司 2025 年 第二次临时股东会（以下简称"本次股东会"）。 本所声明：本所律师仅对本次股东会的召集程序、召开程序、出席会议人员 资格、召集人资格、表决程序、表决结果及会议决议发表法律意见，并不对本次 股东会所审议的议案、议案所涉及的数字及内容发表意见。本所律师同意将本法 律意见书随本次股东会其他信息披露 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、为尊重中小投资者利益，提高中小投资者对公司股东会决议事项的参与 度，本次股东会对中小投资者进行单独计票，中小投资者是指除上市公司董事、 监事、高级管理人员以及单独或者合计持有公司5%以上股份的股东以外的其他 股东； 2、本次股东会不存在增加、变更、否决议案的情况； 3、本次股东会不存在变更前次股东会决议的情况； 证券代码：300294 证券简称：博雅生物 公告编号：2025-082 华润博雅生物制药集团股份有限公司 2025 年第二次临时股东会决议公告 （一）审议通过《关于修订<公司章程>及其附件的议案》 4、本次股东会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 华润博雅生物制药集团股份有限公司(以下简称公司)2025 年第二次临时股 东会通知已于 2025 年 10 月 28 日在中国证券监督管理委员会指定信息披露网站 巨潮资讯网（www.cninfo.com.cn）以公告方式发出。会议于 2025 年 11 月 13 日 在江西省抚州市高新技术产业开发区惠泉路 333 号公司会议室以 ...

万联证券发布研报称，2025年前三季度，血制品板块营业收入同比增速0.30%，其中，Q3同比增速 4.11%；归母净利润同比增速-23.14%，其中，Q3同比增速-30.89%。25Q3血制品上市公司收入端分化明 显，多数公司利润大幅减少。2025年以来血制品股价下跌，主要是行业短期业绩承压，叠加市场情绪变 化所致。血制品产品价格下滑导致公司毛利率下滑，带来现金流压力，血制品公司短期存在业绩压力。 长期看，血制品行业处于整合加速的阶段，头部企业通过并购做大做强。 万联证券主要观点如下： 血制品板块行情 2025年年初以来，血制品板块股价平均下跌8.35%，其中，Q1、Q2、Q3、10月份股价分别下跌3.58%、 0.10%、3.79%、0.61%。年初至11月10日，7家血制品上市公司涨跌不一，其中，股价上涨的包括博晖 创新（300318）、卫光生物（002880）、华兰生物（002007）和派林生物（000403）。分季度看，Q1 股价上涨的只有派林生物，Q2股价下跌的只有天坛生物（600161）和博雅生物（300294），Q3股价上 涨的只有华兰生物和天坛生物，10月份股价下跌的只有天坛生物和派林生物。 ...

Market Overview - The A-share market experienced fluctuations with the Shanghai Composite Index falling by 0.07% to 4000.14 points, the Shenzhen Component Index down by 0.36%, and the ChiNext Index decreasing by 0.39%. The total trading volume in the A-share market was 1.96 trillion RMB, with over 3500 stocks declining. The household appliances, comprehensive, and textile and apparel sectors led the gains, while the electric equipment, machinery, and computer sectors lagged behind [2][8] - In the Hong Kong market, the Hang Seng Index rose by 0.85% and the Hang Seng Technology Index increased by 0.16%. In overseas markets, the Dow Jones rose by 0.68%, the S&P 500 increased by 0.06%, while the Nasdaq fell by 0.26% [2][8] Important News - The Shanghai Stock Exchange International Investor Conference opened on November 12, 2025, focusing on "Value Leadership and Open Empowerment - New Opportunities for International Capital Investment and M&A." The event attracted over 400 representatives from more than 100 well-known investment institutions across Europe, America, Asia-Pacific, and the Middle East. Discussions centered on new opportunities for investment and M&A in China, driven by macroeconomic stability and policy optimization [3][9] Blood Products Sector - The blood products sector has faced profit pressure, with a year-to-date average stock price decline of 8.35%. The sector's revenue growth for the first three quarters of 2025 was 0.30% year-on-year, with a Q3 growth of 4.11%. However, the net profit attributable to shareholders saw a significant decline of 23.14% year-on-year, with Q3 showing a decrease of 30.89% [10][13] - The sales gross margin and net profit margin for Q3 2025 were 40.42% (down 7.26 percentage points year-on-year) and 18.74% (down 10.17 percentage points year-on-year), respectively. The sector's valuation as of November 10, 2025, had a price-to-earnings ratio (TTM) of 30.07, indicating a high percentile ranking since 2020 [13][14] Lithium Battery Sector - The lithium battery sector showed stable demand in the first three quarters of 2025, with overall revenue reaching 636.19 billion RMB, a year-on-year increase of 16.12%, and a net profit of 62.62 billion RMB, up 40.37% year-on-year. Q3 alone saw revenue of 235.43 billion RMB, a 20.42% increase year-on-year, and a net profit of 25.34 billion RMB, up 58.20% year-on-year [14][15] - The battery segment achieved revenue of 417.27 billion RMB in the first three quarters, with a year-on-year growth of 11.92%. In Q3, revenue reached 154.04 billion RMB, reflecting a 16.63% increase year-on-year [16][15] Traditional Chinese Medicine Sector - The traditional Chinese medicine sector faced ongoing performance pressure in Q3 2025, with an overall revenue decline of 1.57% year-on-year and a net profit decrease of 5.25% year-on-year. The sector's sales gross margin was 40.40%, with a net profit margin of 9.21% [20][23] - Among 69 listed companies in the sector, 49 saw stock price increases year-to-date, with notable performers including Wanbangde and Tianmu Pharmaceutical, which both exceeded 100% growth [23][24]

证券代码：300294 证券简称：博雅生物 公告编号：2025-081 华润博雅生物制药集团股份有限公司 本次变更的项目合伙人、签字注册会计师为孙文举先生，2009 年取得中国 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）于 2025 年 3 月 17 日召开了第八届董事会第九次会议，于 2025 年 4 月 10 日召开 2024 年年度股东 大会，审议通过了《关于 2025 年度续聘审计机构的议案》，同意续聘毕马威华 振会计师事务所（特殊普通合伙）（以下简称毕马威华振）为公司 2025 年度财 务审计及内部控制审计机构。具体内容详见公司于 2025 年 3 月 19 日在巨潮资讯 网（网址：http://www.cninfo.com.cn）上披露的《公司关于 2025 年度续聘审计机 构的公告》（公告编号：2025-013）。 近日，公司收到毕马威华振出具的《关于变更华润博雅生物制药集团股份有 限公司 2025 年度审计项目合伙人、签字注册会计师及质量控制复核人的函》， 现将相关变 ...

Group 1 - The core point of the article is that Boya Bio (SZ 300294) announced that as of the announcement date, Gaotejia Group has pledged approximately 37.32 million shares, accounting for 65.42% of its holdings [1] - As of the report, Boya Bio's market capitalization is 12.8 billion yuan [1] - For the first half of 2025, Boya Bio's revenue composition is as follows: blood products account for 84.58%, biochemical drugs account for 8.63%, pharmaceutical distribution accounts for 6.12%, other industries account for 0.65%, and other businesses account for 0.02% [1]

关于持股5%以上股东部分股份质押及解除司法冻结的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）近日收到 5%以上股 东深圳市高特佳投资集团有限公司（以下简称高特佳集团）出具的《关于部分股 份质押及解除司法冻结的告知函》，获悉高特佳集团将所持有公司的部分股份进 行质押及部分股份解除司法冻结，具体事项如下： 一、股东股份质押基本情况 （一）股东本次股份质押基本情况 2025 年 11 月 7 日，高特佳集团将其持有公司的无限售条件流通股 534,524 股（占公司总股本的 0.11%）质押给苏州诚河清洁设备有限公司进行融资，具体 情况如下： 证券代码：300294 证券简称：博雅生物 公告编号：2025-080 华润博雅生物制药集团股份有限公司 | | 是否为 | | | | | 是 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | | | 是否为 | 否 | | 质 | | 质 | | ...

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes venture capital, specifically limited to investments in unlisted companies [1] - The fund is jointly funded by several companies, including Fosun Pharma, Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical [1] Company Contributions - Fosun Pharma's wholly-owned subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is a key contributor to the fund [1] - Other contributors include Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical, indicating a collaborative investment approach among major players in the pharmaceutical industry [1] Investment Focus - The fund is specifically focused on venture investments, which suggests a strategic interest in supporting early-stage pharmaceutical companies [1] - The emphasis on unlisted companies may provide opportunities for high-growth potential investments within the pharmaceutical sector [1]

| | 早,河 都在用的商业查询工具 | 查老板 查风险 | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 国家上加拿球中国发言少了书籍 | 华润(成都)医药产业股权投资基金合伙企业(有限合 8 | 天眼一下 | ■ 应用 ▼ | 商务合作 企业级产品、 ■ 开通会 | | | 基本信息 283 | 法律诉讼 | 经营风险 | 经营信息 | 公司发展 | 知识产权 | | | 工商信息 历史工商信息0 | | | | | | | | 企业名称 | 华润(成都)医药产业股权投资基金合伙企业(有限合伙) | | | | | | | 执行事务合伙人 | 华润医药科技(成都)合伙企业 家庭 医药 | 登记状态 7 | 存续 | | 天眼评分 2 | 97 9 | | | (有限合伙) | 成立日期 | 2025-11-07 | | | | | 统一社会信用代码 2 | 91510100MAK126UR31 | 出资额 | 100000万人民币 | | 立創 | | | 工商注册号 | 510109202136044 | 纳税人识别号 2 | 91510 ...